GNMX ETF — Corgi Genomics & Precision Medicine ETF

Corgi Genomics & Precision Medicine ETF (GNMX)

Updated October 16, 2026.

GNMX is an ETF. its expense ratio is 0.35%. Total return is 38.7% over the past 0.4 years, 34.2 points ahead of SPY at 4.5%.

Corgi Genomics & Precision Medicine ETF is an actively managed equity ETF that invests at least 80% of its assets in companies involved in developing and commercializing genomics and precision medicine technologies for disease detection and targeted therapies. The fund carries an expense ratio of 0.35% and operates as non-diversified. Information about its distribution history and yield is not currently available.

GNMX performance versus SPY

Price and return data through 2026-10-16.

Total return is 38.7% over the past 0.4 years, 34.2 points ahead of SPY at 4.5%.

GNMX key facts

Issuer

Corgi Strategies

Asset type

ETF

Asset class

Equity

Inception date

05/05/2026

Expense ratio

0.35%

Distribution frequency

Annual

Last close

$35.66 (as of 2026-10-16)

AUM

$2,870,921

Average volume

2450.0

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: Corgi Strategies; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GNMX risks and drawbacks

Payments are annual, so cash flow is lumpy versus a monthly fund.

Who may consider GNMX — and who may not

It is a weaker fit for investors who need monthly cash flow (GNMX pays annual). This is educational context, not a recommendation to buy or sell.

More on GNMX

• All tickers starting with G

Frequently asked questions

More securities from Corgi Strategies.